Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Radium ra-223 dichloride
Drug ID BADD_D02586
Description Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Indications and Usage Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB08913
KEGG ID Not Available
MeSH ID Not Available
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 50419-208
UNII RJ00KV3VTG
Synonyms Not Available
Chemical Information
Molecular Formula Not Available
CAS Registry Number 444811-40-9
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pathological fracture12.04.02.006; 16.32.03.007; 15.08.02.008-Not Available
Petechiae24.07.06.004; 01.01.03.002; 23.06.01.003-Not Available
Platelet disorder01.08.03.001-Not Available
Pleural effusion22.05.02.002-
Pre-existing condition improved08.01.03.043-Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009-
Prostate cancer metastatic21.04.02.004; 16.25.01.002-Not Available
Radiculopathy17.10.01.005-
Skin discolouration23.03.03.005-Not Available
Skin exfoliation23.03.07.003-Not Available
Skin hyperpigmentation23.05.01.003-
Skin odour abnormal23.03.03.012-
Skin ulcer24.04.03.007; 23.07.03.003-
Spinal cord compression17.10.01.006-
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014-
Sudden death08.04.01.003; 02.03.04.013-
Thrombocytopenia01.08.01.002-Not Available
Urinary incontinence20.02.02.010; 17.05.01.008-
Urinary retention20.02.02.011-
Uveitis10.02.01.023; 06.04.03.003-
Venous thrombosis24.01.01.008-Not Available
Mobility decreased17.02.05.018; 15.03.05.023; 08.01.03.030-Not Available
Musculoskeletal disorder15.03.05.025-Not Available
Performance status decreased08.01.03.042-Not Available
Brain oedema17.07.02.003; 12.01.10.010-
General physical health deterioration08.01.03.018-Not Available
Anal haemorrhage07.12.03.004; 24.07.02.029-
Tumour haemorrhage24.07.01.028; 16.32.03.008-
Musculoskeletal chest pain22.09.01.001; 15.03.04.012-
Cardiopulmonary failure02.05.01.004; 22.02.06.004-Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages